TRIM31 attenuates microglia-mediated neuroinflammation via targeting TAK1 in vitro and in vivo
Neurochemistry International · 2026-07 · 197 · 106179
DOI: 10.1016/j.neuint.2026.106179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurochemistry International, 2026-07. Verfasst von Xueying Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, The Second Qilu Hospital of Shandong University, Jinan, 250033, China. Hauptthemen laut MEDLINE: Microglia, MAP Kinase Kinase Kinases, Ubiquitin-Protein Ligases, Tripartite Motif Proteins. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Neuroinflammation represents a central pathogenic driver in a spectrum of central nervous system disorders, predominantly mediated by microglial activation and the ensuing release of inflammatory cytokines. While the E3 ubiquitin ligase TRIM31 is implicated in peripheral immunity, its precise function within neuroinflammation defies precise delineation. In this study, we define the role of TRIM31 in microglia-driven neuroinflammation and clarify its molecular mechanism. Utilizing both cellular and murine models of lipopolysaccharide-induced neuroinflammation, we detected a marked induction of TRIM31 expression with LPS stimulation. Genetic knockdown of TRIM31 exacerbated the LPS-triggered upregulation of pro-inflammatory cytokines, including IL-6, TNF-α, and IL-1β. Conversely, TRIM31 overexpression potently suppressed cytokines release and attenuated neuroinflammatory responses in vitro and in vivo. Mechanistic investigations combining transcriptomic profiling and immunoblotting manifested that TRIM31 directly interacts with TAK1, catalyzing its K48-linked polyubiquitination and subsequent proteasomal degradation. This action provokes the downregulation of the NF-κB activation cascade. Collectively, our findings identify TRIM31 as a critical negative regulator of neuroinflammation and underscore its therapeutic potential for treating neuroinflammatory diseases via targeted degradation of TAK1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Blood Transfusion, The Second Qilu Hospital of Shandong University, Jinan, 250033, China.
- Department of Neurosurgery, The Second Qilu Hospital of Shandong University, Jinan, 250033, China.
- Institute of Medical Sciences, The Second Qilu Hospital of Shandong University, Jinan, 250033, China.
- Basic Medical Research Center, Shandong Provincial Third Hospital, Jinan, 250031, China.
- Department of Neurosurgery, The Second Qilu Hospital of Shandong University, Jinan, 250033, China. Electronic address: fanmingde@email.sdu.edu.cn.
Förderung
- Shandong Province Natural Science Foundation
Zitieren
APA
Zhao, X., Zhang, C., Zhang, D., Wang, P., Zhang, L., & Fan, M. (2026). TRIM31 attenuates microglia-mediated neuroinflammation via targeting TAK1 in vitro and in vivo. Neurochemistry International, 197, 106179. https://doi.org/10.1016/j.neuint.2026.106179
Vancouver
Zhao X, Zhang C, Zhang D, Wang P, Zhang L, Fan M. TRIM31 attenuates microglia-mediated neuroinflammation via targeting TAK1 in vitro and in vivo. Neurochemistry International. 2026;197:106179. doi:10.1016/j.neuint.2026.106179
BibTeX
@article{Zhao2026,
author = {Zhao, Xueying and Zhang, Chi and Zhang, Diange and Wang, Peng and Zhang, Lei and Fan, Mingde},
title = {TRIM31 attenuates microglia-mediated neuroinflammation via targeting TAK1 in vitro and in vivo},
journal = {Neurochemistry International},
year = {2026},
volume = {197},
pages = {106179},
doi = {10.1016/j.neuint.2026.106179}
}
EUVIMED